|
From tariffs and onshoring to MFN, the US has seen significant policy developments - but how will these impact pharma in 2026?
|
 |
|
The Amicus acquisition will bolster BioMarin’s rare disease portfolio, while potentially supporting the company’s revenue stream.
|
|
|
In this issue: M&A activity in 2025, China's drug licensing advance, the year ahead, and more.
|
|
|
Ipsen has become the latest Western pharma company to venture to China in search of ADC assets.
|
|
|
The authorisation follows similar greenlights in Europe and the US earlier this year.
|
|
|
Samsung Biologics will acquire the Rockville assets for $280m, with closing expected by the end of first quarter of 2026.
|
|
|
The FDA decision is supported by the GO29781 study in patients with third-line or later FL.
|
|
